Federal Circuit rejects Amgen biosimilar discovery request

11-08-2017

Federal Circuit rejects Amgen biosimilar discovery request

Avosb / iStockphoto.com

The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.


Amgen, Hospira, patent, US Court of Appeals for the Federal Circuit, biosimilar, Biologics Price Competition and Innovation Act, anaemia

LSIPR